GEN News Highlights

Afraxis, Servier Collaborate on Drug Discovery for CNS Disorders

(Page
1
of
1)

Afraxis today announced it is collaborating with French pharma Servier on a drug discovery effort to treat central nervous system (CNS) disorders. The two firms will be using Afraxis' Enhanced Spine Platform (ESP) technology to assess complex neural networks with the goal of evaluating preclinical efficacy and safety in CNS disorders, the San Diego-based drug discovery platform company said. Financial terms of the agreement were not disclosed.

"Servier has a strong commitment to CNS therapeutics, and their interest in the ESP technology further illustrates the potential of this platform in a drug discovery setting," Afraxis president and CEO Carmine Stengone said in a statement. Added Servier’s Christian de Bodinat, director of CNS R&D: "The ESP Technology will allow Servier to fully investigate the broad potential of our drug candidates with the aim of bringing novel medicines into the clinic more rapidly and with greater certainty of action.”

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.